Efficacy and Patterns of Failure for Locally Advanced Cancer of the Cervix Treated With Celebrex (Celecoxib) and Chemoradiotherapy in RTOG 0128
- Statistical Department, Radiation Therapy Oncology Group, Philadelphia, PA (United States)
- Bodine Center for Cancer Treatment, Thomas Jefferson University Hospital, Philadelphia, PA (United States)
- Department of Obstetrics and Gynecology, Wake Forest University School of Medicine, Winston-Salem, NC (United States)
- Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
- Department of Radiation Oncology, University of CA Davis Cancer Center, Sacramento, CA (United States)
- Department of Radiation Oncology, LDS Hospital Radiation Center, Salt Lake City, UT (United States)
- Department of Radiation Oncology, Akron General Medical Center, Akron, OH (United States)
- Radiation Oncology Center, Northwestern Memorial Hospital, Chicago, IL (United States)
- Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC (United States)
Purpose: To determine the efficacy and patterns of initial failure for oral celecoxib, intravenous cisplatin, and 5-fluorouracil and concurrent pelvic radiotherapy in patients with locally advanced cancer of the cervix. Methods and Materials: Patients were treated with concurrent 5-fluorouracil and cisplatin chemotherapy and pelvic radiotherapy and brachytherapy. Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy. The overall and disease-free survival rates were determined. Results: A total of 84 patients were accrued, of whom 78 were eligible. The estimated 2-year disease-free survival and overall survival rate was 69% and 83%, respectively. Of the 78 patients, 24 had treatment failure: 3 with persistent local disease, 9 local only, 2 regional, 4 distant, 1 regional and distant, 1 local and distant, and 2 with local, regional, and distant disease, and 1 had died of cervical cancer without a reported site of first failure and 1 without evidence of disease. Conclusion: At 2 years, the estimated disease-free survival and overall survival rate for patients with advanced cervical cancer who underwent a combination of chemoradiotherapy and celecoxib treatment was 69% and 83%, respectively. Recurrent disease developed in 24 patients, and, of those patients, 18 had a component of locoregional failure as a site of first failure. Thus, locoregional control continues to be problematic after chemoradiotherapy as delivered in our study. The identification of more active biologically targeted therapies is warranted for the treatment of advanced cancer of the cervix.
- OSTI ID:
- 21036205
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 69, Issue 1; Other Information: DOI: 10.1016/j.ijrobp.2007.02.050; PII: S0360-3016(07)00510-X; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Outcomes of Chemoradiotherapy in Cervical Cancer-The Western Australian Experience
Early Clinical Outcome With Concurrent Chemotherapy and Extended-Field, Intensity-Modulated Radiotherapy for Cervical Cancer